Companies · Biotech / Pharma

Pacific Biosciences Of California, Inc.

MENLO PARK · Biotech / Pharma · refined from filed group “Other Technology

Diligence memoA one-page analyst read on Pacific Biosciences Of California, Inc. — recommendation, valuation, rhythm, risks.
$190.3M
Total raised · real
3
Rounds
1.0×
Latest step-up
Top 3%
Sector rank · raised
Series C
Latest stage · inferred · Wed Oct 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Pacific Biosciences Of California, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.95× the median modeled value of Series C Biotech / Pharma companies in 2022–2024 (8 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.7 yr ago; this sector typically re-raises about every 15 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Pacific Biosciences Of California, Inc. is one of 227 Biotech / Pharma companies tracked from MENLO PARK. By capital raised it ranks among the largest (ahead of 98% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$100M+
Issuer revenue
Rule 506(b)
Reg D exemption
165
Investors (latest)
2023-10-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries B · 2013-02-05 Raised $21M (real) Modeled valuation $754M (est)$21M$754MSeries B2013Series C · 2023-08-02 Raised $85M (real) Modeled valuation $1.0B (est)$85M$1.0BSeries C2023Series C · 2023-10-04 Raised $85M (real) Modeled valuation $982M (est)$85M$982MSeries C2023+$85M+$85MCumulative $190M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$20.5M · 2013
Series C$85.0M · 2023
Series C extension$84.8M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$982.0M
Base estimate est.
$268.7M
Conservative case
$1.7B
Upside case
$565.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Series B · modeled $754.0M · 2013-02-052013Series C · modeled $1.0B · 2023-08-02Series C · modeled $982.0M · 2023-10-042023
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
48% low · 74% high
1.44×/yr
Annual markup
1.65×/yr upside case
2.7 yr
Elapsed time used
2.7 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
64 mo
Avg between rounds
$17.9M/yr
Capital velocity
13.4 yr
On record since
2013
First round
3
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 34× above median
This company$190.3M
Sector median$5.6M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.8× above median
This company$84.8M
Sector median$48.1M
Modeled value — vs sector median (estimate, all stages) 32× above median
This company$982.0M
Sector median$30.5M

Raised more than 98% of sector peers (real $). Modeled value above 95% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 8.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Sherlock Biosciences, Inc. · Series C Raised $112.8M · modeled $1.7B (est)Sudo Biosciences, Inc. · Series C Raised $73.1M · modeled $685.8M (est)Elephas Biosciences Corp · Series C Raised $113.7M · modeled $560.6M (est)NOLA PharmaHoldings, LLC · Series C Raised $48.1M · modeled $448.1M (est)Belenos Biosciences, Inc. · Series C Raised $48.0M · modeled $421.4M (est)TwinStrand Biosciences, Inc. · Series C Raised $85.0M · modeled $132.4M (est)Manus Bio Inc. · Series C Raised $118.0M · modeled $108.4M (est)Pacific Biosciences Of California, Inc. (this company) Raised $190.3M · modeled $982.0M (est)Pacific Biosciences Of California, Inc.
CompanyStageRaised · realValue · estvs peer med.
Sherlock Biosciences, Inc.Series C$112.8M$1.7B3.29×
Pacific Biosciences Of California, Inc. this companySeries C$190.3M$982.0M1.95×
Sudo Biosciences, Inc.Series C$73.1M$685.8M1.36×
Elephas Biosciences CorpSeries C$113.7M$560.6M1.11×
NOLA PharmaHoldings, LLCSeries C$48.1M$448.1M0.89×
Belenos Biosciences, Inc.Series C$48.0M$421.4M0.84×
TwinStrand Biosciences, Inc.Series C$85.0M$132.4M0.26×
Manus Bio Inc.Series C$118.0M$108.4M0.21×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$20.5M2013-02-05$113.9M$754.0M85%
Series C$85.0M2023-08-02$566.7M$1.0B90%
Series C$84.8M2023-10-04$565.1M$982.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$20.5M2013-02-05
    • First recorded raise — entered as Series B.
    • 4 investors on this round.
  2. Series C$85.0M2023-08-02
    • Raised again after 126 mo — slower than the ~15 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 47 investors on this round.
  3. Series C$84.8M2023-10-04
    • Came back fast: 2 mo vs the ~15 mo sector norm.
    • Round roughly the size of the prior one.
    • 165 investors on this round.
Intelligence
2029 ~Q1
Modeled next raise · ~64mo cadence
$84.8M
Modeled next size est.range $84.8M$135.6M
1.0×
Last step-up
$17.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David B Singer4 other2013-02
Michael Hunkapiller3 other2013-02
Brook H Byers2 other2013-02
Randall S Livingston2 other2013-02
David Botstein1 other2023-08
Christian O. Henry2023-08
David S. Meline2023-10
David W Botstein2013-02
Hannah A. Valantine2023-08
Hannah A. Valentine2023-10
Jeff A. Eidel2023-10
Jeff G. Eidel2023-08
J Michael P Phillips2013-02
John F. Milligan2023-08
Kathy F. Ordonez2023-08
Kevin P Corcoran2013-02
Lucy A. Shapiro2023-10
Lucy F. Shapiro2023-08
Lucy S Shapiro2013-02
Mark A. Van Oene2023-10
Mark G. Van Oene2023-08
Marshall F. Mohr2023-08
Marshall S Mohr2013-02
Susan A. Kim2023-10
Registry & provenance

Pacific Biosciences Of California, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1299130
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Coherus BioSciences, Inc.Biotech / PharmaSeries C$160.7M$258.3Msame sector · same stage
Imago BioSciences, Inc.Biotech / PharmaSeries C$137.5M$2.7Bsame sector · same stage
Cardiodx IncBiotechnologySeries C$174.0M$742.4Mnetwork1 shared operator · same stage
Life Biosciences LLCBiotech / PharmaSeries C$123.4M$2.8Bsame sector · same stage
Manus Bio Inc.Biotech / PharmaSeries C$118.0M$108.4Msame sector · same stage
Elephas Biosciences CorpBiotech / PharmaSeries C$113.7M$560.6Msame sector · same stage
Sherlock Biosciences, Inc.Biotech / PharmaSeries C$112.8M$1.7Bsame sector · same stage
TwinStrand Biosciences, Inc.Biotech / PharmaSeries C$85.0M$132.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Biopharmaceutical Research CoOther TechnologySeries B$6.9M87%
Surf Bio, Inc.Biotech / PharmaSeries B$287.9M86%
Continuum Biosciences, Inc.Biotech / PharmaPre-Seed$25.6M86%
PharmaCCX, Inc.Biotech / PharmaSeries A$45.1M86%
Q Bio, Inc.Biotech / PharmaSeries B$213.8M86%
Arcadia Biosciences, Inc.Biotech / PharmaSeries B$7.8M86%
Sudo Biosciences, Inc.Biotech / PharmaSeries C$685.8M86%
Caladan Bio Inc.Biotech / PharmaSeries A$32.2M85%
Frequently asked
How much funding has Pacific Biosciences Of California, Inc. raised?
Pacific Biosciences Of California, Inc. has raised approximately $190.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Pacific Biosciences Of California, Inc.'s estimated valuation?
Provath's modeled valuation for Pacific Biosciences Of California, Inc. is approximately $982.0M (modeled range $268.7M–$1.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pacific Biosciences Of California, Inc. at?
Pacific Biosciences Of California, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Oct 04.
What does Pacific Biosciences Of California, Inc. do and where is it based?
Pacific Biosciences Of California, Inc. operates in the Biotech / Pharma sector, based in MENLO PARK.
Explore related

See where Pacific Biosciences Of California, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pacific Biosciences Of California, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.